BioNTech SE
NASDAQ:BNTX
BioNTech SE
Net Income (Common)
BioNTech SE
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
BioNTech SE
NASDAQ:BNTX
|
Net Income (Common)
€930.3m
|
CAGR 3-Years
296%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Net Income (Common)
-€460.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Net Income (Common)
-€260.2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Net Income (Common)
-€97m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Net Income (Common)
€127m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
15%
|
|
Formycon AG
XETRA:FYB
|
Net Income (Common)
€75.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
See Also
What is BioNTech SE's Net Income (Common)?
Net Income (Common)
930.3m
EUR
Based on the financial report for Dec 31, 2023, BioNTech SE's Net Income (Common) amounts to 930.3m EUR.
What is BioNTech SE's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
296%
Over the last year, the Net Income (Common) growth was -90%. The average annual Net Income (Common) growth rates for BioNTech SE have been 296% over the past three years .